{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:53Z","timestamp":1777858373708,"version":"3.51.4"},"reference-count":134,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1995,5,1]],"date-time":"1995-05-01T00:00:00Z","timestamp":799286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[1995,5]]},"abstract":"<jats:p>Neurochemical investigations of Tourette's syndrome (TS) suggest that the symptoms of this disorder may be the result of an imbalance among several neurotransmitter and\/or neuromodulator systems. Neurochemicals which have been studied included: catecholamines; acetylcholine; tryptophan and its metabolites; the amino acids \u03b3-aminobutyric acid (GABA), glutamate, phenylalanine and p-tyrosine; trace amines; opioid peptides; cyclic AMP and androgenic hormones. A suitable animal model of TS would do much to advance our understanding of this disorder, and there are some interesting recent developments in this regard.<\/jats:p>","DOI":"10.1177\/026988119500900311","type":"journal-article","created":{"date-parts":[[2007,3,17]],"date-time":"2007-03-17T23:45:17Z","timestamp":1174175117000},"page":"273-280","source":"Crossref","is-referenced-by-count":9,"title":["Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update"],"prefix":"10.1177","volume":"9","author":[{"given":"G.B.","family":"Baker","sequence":"first","affiliation":[{"name":"Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.R.","family":"Chokka","sequence":"additional","affiliation":[{"name":"Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1995,5,1]]},"reference":[{"key":"atypb1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","edition":"4"},{"key":"atypb2","first-page":"123","volume":"58","author":"Anderson G.M.","year":"1992","journal-title":"Advances in neurology"},{"key":"atypb3","unstructured":"Ang A., Borison R., Dysken M., Davis J.M. (1982) Reduced excretion of MHPG in Tourette's syndrome . In Friedhoff A H, Chase T N (eds), Advances in neurology, Vol. 35. Raven Press, NY , pp. 171-175"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(92)90142-P"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1007\/BF03159925"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(91)90207-3"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00966752"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1007\/BF03160031"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(90)90097-O"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.3.4.417"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(92)90008-Q"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(92)90060-G"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2.4.408"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-0614-7_8"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91064-S"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.3.437"},{"key":"atypb17","unstructured":"Brooks D.J., Turjanski N., Sawle G.V., Playford E.D., Lees A.J. (1992) PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 227-232"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00002"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410060109"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.9.4155"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91516-4"},{"key":"atypb22","unstructured":"Chappell P.B., Leckman J.F., Riddle M.A., Anderson G.M., Listwack S.J., Ort S.I., Hardin M.T., Scahill L.D., Cohen D.J. (1992) Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 253-262"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(93)90084-T"},{"key":"atypb24","author":"Chokka P.R.","year":"1995","journal-title":"Metab Brain Dis"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770260123015"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)61046-3"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320360410"},{"key":"atypb28","volume-title":"Tourette syndrome and human behavior","author":"Comings D.E.","year":"1990"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93123-I"},{"key":"atypb30","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/0140-6736(93)93123-I","volume":"341","author":"Comings D.E.","year":"1993","journal-title":"Lancet"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1982.tb05365.x"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199504000-00007"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.157.5.762"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(94)90005-1"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.5.1.108-a"},{"key":"atypb36","unstructured":"Dingledine R., McBain C.J. (1994) Excitatory amino acid transmitters. In Siegel G J, Agranoff B W , Albers R W, Molinoff P B (eds), Basic neurochemistry. 5th Edn, Raven Press, NY, pp.367-387"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.1992.11701499"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14493.x"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1007\/BF03160084"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1177\/026988119400800105"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(92)90227-3"},{"key":"atypb42","first-page":"863","volume":"46","author":"Elia J.","year":"1993","journal-title":"Therapeutic guidelines. Drugs"},{"key":"atypb43","author":"Fang J.","year":"1995","journal-title":"Psychopharmacology"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1159\/000139195"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.3.378"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(94)90041-8"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.3.449"},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540160099012"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.1.93"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470080505"},{"key":"atypb51","unstructured":"Goetz C.G. (1992) Clonidine and clonazepam in Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press. NY, pp. 245-251"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.3928\/0090-4481-19880601-08"},{"key":"atypb53","unstructured":"Haber S.N., Wolfer D. (1992) Basal ganglia peptidergic staining in Tourette syndrome: a follow-up study. In Chase T N , Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY , pp. 145-150"},{"key":"atypb54","first-page":"235","volume":"85","author":"Handley S.L.","year":"1992","journal-title":"Adv Biosci"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431641"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00006"},{"key":"atypb57","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90931-6"},{"key":"atypb58","first-page":"417","volume":"267","author":"Henderson M.G.","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb59","doi-asserted-by":"publisher","DOI":"10.3928\/0048-5713-19930601-07"},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90859-G"},{"key":"atypb61","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820090067011"},{"key":"atypb62","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540030052014"},{"key":"atypb63","doi-asserted-by":"publisher","DOI":"10.1139\/y82-054"},{"key":"atypb64","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(90)91005-C"},{"key":"atypb65","doi-asserted-by":"publisher","DOI":"10.1002\/med.2610050202"},{"key":"atypb66","unstructured":"Kaplan H.I., Sadock B.J., Grebb J.A. (1994) Tic disorders. In Kaplan and Sadock's synopsis of psychiatry. 7th edn, Willams & Wilkins, Baltimore, MD, pp. 1080-1087"},{"key":"atypb67","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.10.1064"},{"key":"atypb68","unstructured":"Koslow S.H., Cross C.K. (1982) Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications. In Friedhoff A J, Chase T N (eds), Advances in neurology, Vol. 35. Raven Press, NY, pp. 185-197"},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300105"},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006073222314"},{"key":"atypb71","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)61504-1"},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90575-9"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810280040006"},{"key":"atypb74","unstructured":"Leckman J.F., Pauls D.L., Peterson B.S., Riddle M.A., Anderson G.M., Cohen D. (1992) Pathogenesis of Tourette syndrome: clues from the clinical phenotype and natural history. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 15-24"},{"key":"atypb75","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1380241"},{"key":"atypb76","unstructured":"LeWitt P. A (1992) Therapeutics of Tourette syndrome: new medication approaches. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp.263-270"},{"key":"atypb77","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91502-7"},{"key":"atypb78","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198812000-00012"},{"key":"atypb79","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320370043028"},{"key":"atypb80","first-page":"109","volume":"335","author":"Manier D.H.","year":"1987","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"atypb81","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198506000-00009"},{"key":"atypb82","doi-asserted-by":"crossref","unstructured":"Martin L.L., Baker G.B., Wood P.L. (1988) Tryptamine turnover: effects of drugs. In Boulton A A, Juorio A V, Downer R G H (eds), Trace amines: comparative and clinical neurobiology. Humana Press, Clifton, NJ, pp. 95-104","DOI":"10.1007\/978-1-4612-4602-2_9"},{"key":"atypb83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91553-9"},{"key":"atypb84","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950040046006"},{"key":"atypb85","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)38553-4"},{"key":"atypb86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb02628.x"},{"key":"atypb87","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(88)80062-9"},{"key":"atypb88","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.1.139b"},{"key":"atypb89","doi-asserted-by":"publisher","DOI":"10.1139\/y93-054"},{"key":"atypb90","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(92)90029-U"},{"key":"atypb91","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4530(94)90014-0"},{"key":"atypb92","first-page":"393","volume":"23","author":"Olianas M.C.","year":"1983","journal-title":"Mol Pharmacol"},{"key":"atypb93","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245008"},{"key":"atypb94","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb05764.x"},{"key":"atypb95","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.11.030188.000401"},{"key":"atypb96","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4530(92)90015-Y"},{"key":"atypb97","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.9.1166"},{"key":"atypb98","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)91563-X"},{"key":"atypb99","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(92)90115-G"},{"key":"atypb100","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199402030-00003"},{"key":"atypb101","first-page":"117","volume":"30","author":"Reveley M.A.","year":"1994","journal-title":"J Psychopharmacol Suppl"},{"key":"atypb102","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.2.147"},{"key":"atypb103","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.152.3.383"},{"key":"atypb104","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199006000-00005"},{"key":"atypb105","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199209000-00001"},{"key":"atypb106","first-page":"103","volume":"1","author":"Ross M.S.","year":"1978","journal-title":"Am J Psychiatr"},{"key":"atypb107","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(93)90030-J"},{"key":"atypb108","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410180322"},{"key":"atypb109","first-page":"689","volume":"220","author":"Scatton B.","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb110","first-page":"678","volume":"220","author":"Scatton B.","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb111","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.62041382.x"},{"key":"atypb112","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.06-08-02235.1986"},{"key":"atypb113","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199010000-00003"},{"key":"atypb114","unstructured":"Shapiro A.K., Shapiro E., Sweet R.D. (1981) Treatment of tics and Tourette syndrome. In Barbeau A (ed.), Disorders of movement. J B Lippincott, Philadelphia, PA, pp. 105-132"},{"key":"atypb115","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810080052006"},{"key":"atypb116","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-5312-9_21"},{"key":"atypb117","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91392-Y"},{"key":"atypb118","unstructured":"Singer H.S. (1992) Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome. In Chase TN, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 135-144"},{"key":"atypb119","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199101000-00002"},{"key":"atypb120","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410120408"},{"key":"atypb121","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04050180078022"},{"key":"atypb122","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270415"},{"key":"atypb123","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300408"},{"key":"atypb124","unstructured":"Singer H.S., Wong D.F., Brown J.E., Brandt J., Krafft L., Shaya E., Dannals R.F., Wagner H.N. Jr (1992) Positron emission tomography evaluation of dopamine D2 receptors in adults with Tourette syndrome. In Chase T N, Friedhoff A J, Cohen D J (eds), Advances in neurology, Vol. 58. Raven Press, NY, pp. 233-239"},{"key":"atypb125","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(84)90103-3"},{"key":"atypb126","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.138.2.240"},{"key":"atypb127","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100048769"},{"key":"atypb128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90212-X"},{"key":"atypb129","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760180095012"},{"key":"atypb130","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.6.688"},{"key":"atypb131","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.1.105"},{"key":"atypb132","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90223-2"},{"issue":"1","key":"atypb133","first-page":"S593","volume":"9","author":"Wong D.F.","year":"1989","journal-title":"J Cerebral Blood Flow Metab"},{"key":"atypb134","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)60509-4"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119500900311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119500900311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:02Z","timestamp":1777507922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/026988119500900311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,5]]}},"alternative-id":["10.1177\/026988119500900311"],"URL":"https:\/\/doi.org\/10.1177\/026988119500900311","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5]]}}}